Improving Venous Thromboembolism Prophylaxis

Phase 4

Completed

• Conditions: Venous Thromboembolism; Delivery of Health Care; Quality Improvement
• Interventions: Other: VTE-P Tollgate; Other: BLAZE Pop up; Other: Usual Care

• Registration Number: NCT01304108
• Lead Sponsor: Mayo Clinic

Brief Summary

Preventing the formation of blood clots in the veins so they do not injure leg veins or travel to the lungs, also called venous thromboembolism prophylaxis (VTE-P) is an essential component of safe in-patient care, yet it is deployed sub-optimally in many hospitals, including The investigators own. Two prior VTE-P improvement projects were completed at Mayo Clinic hospitals, one in the Department of Medicine, and the other in selected divisions of the Department of Surgery. Both projects resulted in marked improvement in the percentage of patients receiving appropriate VTE-P. This project seeks to utilize the lessons learned from these two pilots along with known best practices for \"spreading\" to deploy methods that enhance VTE-P to the entire hospitalized population. The investigators seek appropriate VTE-P rates exceeding 95%.

Detailed Description

Venous thromboembolism prophylaxis (VTE-P) is an essential component of safe in-patient care, yet it is deployed sub-optimally in many hospitals, including our own. Two prior VTE-P improvement projects were completed at Mayo Clinic hospitals, one in the Department of Medicine, and the other in selected divisions of the Department of Surgery. Both projects resulted in marked improvement in the percentage of patients receiving appropriate VTE-P. This project seeks to utilize the lessons learned from these two pilots along with known best practices for \"spreading\" to deploy methods that enhance VTE-P to the entire hospitalized population. The investigators seek appropriate VTE-P rates exceeding 95%. This began as a quality improvement project. The investigators have taken baseline measures of VTE-P rates in our hospitals, intervened with various electronic prompts to use appropriate VTE-P, and have and will re-measure VTE-P rates. The investigators intend to present and publish our methods and results so that lessons learned may be shared and applied elsewhere.

Study Timeline

• Study Start: 2009-01
• Primary Completion: 2010-05
• Study Completion: 2010-05
• Study First Submitted: 2010-07-09
• Status Verified: 2011-02
• Study First Submitted QC: 2011-02-24
• Last Update Submitted: 2011-02-24
• Study First Posted: 2011-02-25
• Last Update Posted: 2011-02-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 3000

Inclusion Criteria

• Inpatients with age > 17 years old

Read More

Exclusion Criteria

• Outpatients
• Inpatients with age less than or equal to 17 years old

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Order Set	VTE-P Tollgate	Insertion of VTE-P Order Set "tollgate" in all active admission and transfer orders.
Clinical Decision Support Pop-up	BLAZE Pop up	Deploy rules-based pop-up that reminds ordering clinicians when patients do not have an active VTE-P plan.
Usual Care	Usual Care	Usual care, without the experimental additions

Primary Outcome Measures

Name	Time	Method
% of in patients with an appropriate VTE prophylaxis plan	Baseline to 1 month	The investigators will measure the number of patients in a statistically valid random sample of hospitalized patients who have a VTE-prophylaxis plan consistent with current recommendations.

Secondary Outcome Measures

Name	Time	Method
Clinically significant complications of VTE-P anticoagulant therapy	baseline to 1 month	The investigators will determine the rate of bleeding complications in inpatients using a statistically valid random sample of hospitalized patients. The investigators will also determine the rate of procedure delays due to VTE-P related anticoagulation.

Trial Locations

Locations (1)

Mayo Clinic in Rochester; 🇺🇸 Rochester, Minnesota, United States